NASDAQ:RVNC - Revance Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$31.15 +0.40 (+1.30 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$31.15
Today's Range$30.55 - $31.25
52-Week Range$21.15 - $37.45
Volume127,757 shs
Average Volume239,444 shs
Market Capitalization$1.13 billion
P/E Ratio-7.77
Dividend YieldN/A
Beta1.34

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio11.89
Quick Ratio11.89

Price-To-Earnings

Trailing P/E Ratio-7.77
Forward P/E Ratio-8.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales4,406.53
Cash FlowN/A
Price / CashN/A
Book Value$6.43 per share
Price / Book4.84

Profitability

EPS (Most Recent Fiscal Year)($4.01)
Net Income$-120,580,000.00
Net Margins-33,807.37%
Return on Equity-63.68%
Return on Assets-54.86%

Miscellaneous

Employees134
Outstanding Shares36,780,000

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc. (NASDAQ:RVNC) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.26. The biopharmaceutical company earned $0.19 million during the quarter, compared to analysts' expectations of $0.15 million. Revance Therapeutics had a negative net margin of 33,807.37% and a negative return on equity of 63.68%. View Revance Therapeutics' Earnings History.

What price target have analysts set for RVNC?

12 brokerages have issued 1 year price objectives for Revance Therapeutics' stock. Their predictions range from $34.00 to $60.00. On average, they anticipate Revance Therapeutics' stock price to reach $46.1818 in the next year. View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (5/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Today, RVNC announced four new senior roles for its commercialization team: Dustin Sjuts as VP Strategy and Sales, Aesthetics & Therapeutics; Ben Putman as VP Digital; Marc Korenberg as Sr Director of Commercial Operations; and Erica Bazerkanian has been promoted to VP Marketing, Aesthetics & Therapeutics." (4/2/2018)

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 55)
  • Mr. Todd Erik Zavodnick, Chief Commercial Officer and Pres of Aesthetics & Therapeutics (Age 46)
  • Ms. Lauren P. Silvernail, CFO, Chief Bus. Officer & Sec. (Age 59)
  • Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

Has Revance Therapeutics been receiving favorable news coverage?

Media stories about RVNC stock have been trending negative on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Revance Therapeutics earned a daily sentiment score of -0.29 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 48.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (9.36%), Franklin Resources Inc. (8.64%), BlackRock Inc. (6.56%), Millennium Management LLC (4.06%), Northern Trust Corp (0.92%) and Fosun International Ltd (0.87%). Company insiders that own Revance Therapeutics stock include Curtis Ruegg, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Rothschild Asset Management Inc. and Blair William & Co. IL. Company insiders that have sold Revance Therapeutics company stock in the last year include L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Insider Buying and Selling for Revance Therapeutics.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Fosun International Ltd, BlackRock Inc., OppenheimerFunds Inc., Northern Trust Corp, DekaBank Deutsche Girozentrale, Federated Investors Inc. PA and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $31.15.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $1.13 billion and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (RVNC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Revance Therapeutics (NASDAQ:RVNC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Revance Therapeutics in the last 12 months. Their average twelve-month price target is $46.1818, suggesting that the stock has a possible upside of 48.26%. The high price target for RVNC is $60.00 and the low price target for RVNC is $34.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.893.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.1818$46.1818$46.1111$36.00
Price Target Upside: 48.26% upside50.09% upside37.24% upside35.85% upside

Revance Therapeutics (NASDAQ:RVNC) Consensus Price Target History

Price Target History for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ:RVNC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00HighView Rating Details
4/20/2018GuggenheimReiterated RatingHoldHighView Rating Details
4/20/2018MizuhoLower Price TargetBuy$54.00 ➝ $48.00HighView Rating Details
3/26/2018Needham & Company LLCInitiated CoverageBuy$42.00LowView Rating Details
3/5/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$60.00MediumView Rating Details
3/1/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00HighView Rating Details
3/1/2018William BlairReiterated RatingOutperformMediumView Rating Details
1/17/2018CowenSet Price TargetBuy$55.00LowView Rating Details
12/19/2017BarclaysSet Price TargetOverweight ➝ Buy$40.00HighView Rating Details
12/8/2017SunTrust BanksBoost Price TargetBuy$53.00MediumView Rating Details
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$34.00MediumView Rating Details
6/8/2017AegisReiterated RatingBuy$36.00MediumView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Revance Therapeutics (NASDAQ:RVNC) Earnings History and Estimates Chart

Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ:RVNC) Earnings Estimates

2018 EPS Consensus Estimate: ($3.04)
2019 EPS Consensus Estimate: ($4.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.20)($0.20)($0.20)
Q2 20183($0.96)($0.85)($0.92)
Q3 20183($0.99)($0.91)($0.96)
Q4 20183($1.03)($0.91)($0.96)
Q1 20191($0.96)($0.96)($0.96)
Q2 20191($0.99)($0.99)($0.99)
Q3 20191($1.06)($1.06)($1.06)
Q4 20191($1.13)($1.13)($1.13)

Revance Therapeutics (NASDAQ RVNC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.71)($0.97)$0.15 million$0.19 millionViewN/AView Earnings Details
2/28/2018Q4 2017($0.99)($1.14)$0.09 million$0.04 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.95)($1.01)$0.05 million$0.08 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.93)($0.90)$0.05 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
3/26/2014Q4 2013($47.11)$0.31 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Revance Therapeutics (NASDAQ:RVNC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Revance Therapeutics (NASDAQ RVNC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 92.85%
Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ RVNC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018Lauren P SilvernailCFOSell2,874$30.25$86,938.5065,497View SEC Filing  
3/22/2018Lauren P SilvernailCFOSell3,431$30.85$105,846.3568,371View SEC Filing  
3/16/2018L Daniel BrowneCEOSell6,452$31.64$204,141.28130,208View SEC Filing  
3/16/2018Phyllis GardnerDirectorSell5,333$31.51$168,042.835,250View SEC Filing  
3/13/2018Lauren P SilvernailCFOSell25,867$34.50$892,411.5098,821View SEC Filing  
3/9/2018Lauren P SilvernailCFOSell20,000$32.00$640,000.0082,954View SEC Filing  
3/7/2018L Daniel BrowneCEOSell27,283$31.43$857,504.69131,208View SEC Filing  
3/7/2018Lauren P SilvernailCFOSell10,000$31.50$315,000.0082,954View SEC Filing  
11/22/2017L Daniel BrowneCEOSell7,600$24.94$189,544.00133,188View SEC Filing  
11/7/2017Lauren P SilvernailCFOSell10,000$26.83$268,300.0059,006View SEC Filing  
11/7/2017Mark J FoleyDirectorBuy20,000$26.96$539,200.006,000View SEC Filing  
10/18/2017L Daniel BrowneCEOSell7,662$26.16$200,437.92140,788View SEC Filing  
10/12/2017Lauren P SilvernailCFOSell11,164$26.67$297,743.88View SEC Filing  
9/20/2017L Daniel BrowneCEOSell7,600$23.58$179,208.00148,450View SEC Filing  
8/23/2017L Daniel BrowneCEOSell22,800$22.76$518,928.00178,850View SEC Filing  
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55183,932View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40183,932View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.6036,566View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00184,627View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00195,627View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00208,449View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00219,627View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.0024,944View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.0026,264View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.0026,264View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.0026,264View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.0017,264View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.0018,027View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.8334,001View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.0018,027View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Revance Therapeutics (NASDAQ RVNC) News Headlines

Source:
DateHeadline
Revance (RVNC) Reports Publication of Positive 24-Week Duration of Effect Results from CD Phase 2 Trial in Movement Disorders Clinical PracticeRevance (RVNC) Reports Publication of Positive 24-Week Duration of Effect Results from CD Phase 2 Trial in Movement Disorders Clinical Practice
www.streetinsider.com - May 25 at 8:55 AM
Revance Therapeutics Inc. (RVNC) CFO Lauren P. Silvernail Sells 2,874 SharesRevance Therapeutics Inc. (RVNC) CFO Lauren P. Silvernail Sells 2,874 Shares
www.americanbankingnews.com - May 24 at 10:10 PM
Revances RT002 shows positive effect in mid-stage neck spasm studyRevance's RT002 shows positive effect in mid-stage neck spasm study
seekingalpha.com - May 24 at 4:55 PM
Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical PracticeRevance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice
finance.yahoo.com - May 24 at 4:55 PM
FY2018 EPS Estimates for Revance Therapeutics Inc. (RVNC) Lifted by AnalystFY2018 EPS Estimates for Revance Therapeutics Inc. (RVNC) Lifted by Analyst
www.americanbankingnews.com - May 24 at 8:23 AM
 Analysts Expect Revance Therapeutics Inc. (RVNC) Will Announce Quarterly Sales of $930,000.00 Analysts Expect Revance Therapeutics Inc. (RVNC) Will Announce Quarterly Sales of $930,000.00
www.americanbankingnews.com - May 18 at 5:47 AM
Revance Therapeutics Inc. (RVNC) Expected to Post Earnings of -$0.92 Per ShareRevance Therapeutics Inc. (RVNC) Expected to Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - May 16 at 3:14 AM
Revance Therapeutics Inc. (RVNC) Given Average Rating of "Buy" by BrokeragesRevance Therapeutics Inc. (RVNC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 16 at 1:24 AM
Revance to Participate in the UBS Global Healthcare ConferenceRevance to Participate in the UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 5:12 PM
Revance Therapeutics (RVNC) Downgraded to Hold at Zacks Investment ResearchRevance Therapeutics (RVNC) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 1:21 PM
Q2 2018 EPS Estimates for Revance Therapeutics Inc. (RVNC) Reduced by SunTrust BanksQ2 2018 EPS Estimates for Revance Therapeutics Inc. (RVNC) Reduced by SunTrust Banks
www.americanbankingnews.com - May 14 at 1:42 AM
Revance Therapeutics (RVNC) Raised to Buy at Zacks Investment ResearchRevance Therapeutics (RVNC) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:23 PM
Revance Therapeutics (RVNC) CEO Dan Browne on Q1 2018 Results - Earnings Call TranscriptRevance Therapeutics' (RVNC) CEO Dan Browne on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 9:32 AM
Analysts Issue Forecasts for Revance Therapeutics Inc.s Q2 2018 Earnings (RVNC)Analysts Issue Forecasts for Revance Therapeutics Inc.'s Q2 2018 Earnings (RVNC)
www.americanbankingnews.com - May 11 at 9:38 AM
Q2 2018 EPS Estimates for Revance Therapeutics Inc. Lowered by Analyst (RVNC)Q2 2018 EPS Estimates for Revance Therapeutics Inc. Lowered by Analyst (RVNC)
www.americanbankingnews.com - May 11 at 9:35 AM
BRIEF-Revance Reports Qtrly Loss Per Share $0.97BRIEF-Revance Reports Qtrly Loss Per Share $0.97
www.reuters.com - May 9 at 4:53 PM
Revance Therapeutics Announces Two Recent Additions to Its Management TeamRevance Therapeutics Announces Two Recent Additions to Its Management Team
finance.yahoo.com - May 9 at 4:53 PM
Edited Transcript of RVNC earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of RVNC earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 9 at 4:53 PM
Revance Therapeutics (RVNC) Issues  Earnings Results, Misses Estimates By $0.26 EPSRevance Therapeutics (RVNC) Issues Earnings Results, Misses Estimates By $0.26 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
Revance Therapeutics (RVNC) PT Set at $50.00 by Cantor FitzgeraldRevance Therapeutics (RVNC) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 12:08 PM
Revance Therapeutics misses by $0.26, misses on revenueRevance Therapeutics misses by $0.26, misses on revenue
seekingalpha.com - May 9 at 9:06 AM
Revance Releases First Quarter 2018 ResultsRevance Releases First Quarter 2018 Results
finance.yahoo.com - May 8 at 4:52 PM
Revance Therapeutics (RVNC) Set to Announce Quarterly Earnings on TuesdayRevance Therapeutics (RVNC) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 2 at 9:42 PM
Revance Therapeutics (RVNC) Lowered to "Sell" at Zacks Investment ResearchRevance Therapeutics (RVNC) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 1:35 PM
Revance Therapeutics (RVNC) Stock Rating Lowered by BidaskClubRevance Therapeutics (RVNC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - May 1 at 8:12 AM
Revance Therapeutics Took the Least Resistance Path, Turned LowerRevance Therapeutics Took the Least Resistance Path, Turned Lower
finance.yahoo.com - April 30 at 4:44 PM
Revance Therapeutics Inc. (RVNC) Expected to Post Quarterly Sales of $8.48 MillionRevance Therapeutics Inc. (RVNC) Expected to Post Quarterly Sales of $8.48 Million
www.americanbankingnews.com - April 30 at 3:00 AM
Revance Therapeutics Inc. (RVNC) Expected to Post Earnings of -$0.63 Per ShareRevance Therapeutics Inc. (RVNC) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - April 28 at 1:23 PM
Oversold Conditions For Revance Therapeutics (RVNC)Oversold Conditions For Revance Therapeutics (RVNC)
www.nasdaq.com - April 27 at 9:30 AM
Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
finance.yahoo.com - April 25 at 4:55 PM
Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
finance.yahoo.com - April 24 at 5:01 PM
Revance Therapeutics (RVNC) "Hold" Rating Reaffirmed at GuggenheimRevance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Guggenheim
www.americanbankingnews.com - April 20 at 4:17 PM
Revance Therapeutics (RVNC) Rating Increased to Hold at BidaskClubRevance Therapeutics (RVNC) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM
Mizuho Trims Revance Therapeutics (RVNC) Target Price to $48.00Mizuho Trims Revance Therapeutics (RVNC) Target Price to $48.00
www.americanbankingnews.com - April 20 at 7:46 AM
Revance sees U.S. marketing application for Botox competitor RT002 in H1 2019Revance sees U.S. marketing application for Botox competitor RT002 in H1 2019
seekingalpha.com - April 19 at 4:58 PM
Revance Investor Day Highlights New Neuroscience Indications in DevelopmentRevance Investor Day Highlights New Neuroscience Indications in Development
www.bizjournals.com - April 19 at 4:58 PM
Revance Therapeutics: Cramers Top TakeawaysRevance Therapeutics: Cramer's Top Takeaways
finance.yahoo.com - April 19 at 9:00 AM
BidaskClub Downgrades Revance Therapeutics (RVNC) to HoldBidaskClub Downgrades Revance Therapeutics (RVNC) to Hold
www.americanbankingnews.com - April 18 at 5:18 PM
Revance Therapeutics (RVNC) Given a $28.00 Price Target by Piper Jaffray AnalystsRevance Therapeutics (RVNC) Given a $28.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 15 at 11:42 PM
Revance Therapeutics Inc. (RVNC) Expected to Announce Quarterly Sales of $12.68 MillionRevance Therapeutics Inc. (RVNC) Expected to Announce Quarterly Sales of $12.68 Million
www.americanbankingnews.com - April 13 at 2:37 AM
Revance Therapeutics (RVNC) Upgraded to "Buy" by Zacks Investment ResearchRevance Therapeutics (RVNC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:01 PM
Revance Therapeutics Inc. (RVNC) Expected to Announce Earnings of -$0.63 Per ShareRevance Therapeutics Inc. (RVNC) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - April 11 at 3:13 PM
Revance Therapeutics Inc Is Set to Shake Up the Botox MarketRevance Therapeutics Inc Is Set to Shake Up the Botox Market
investorplace.com - April 4 at 11:01 AM
Revance beefs up commercial team ahead of launch of Botox competitor RT002Revance beefs up commercial team ahead of launch of Botox competitor RT002
seekingalpha.com - April 3 at 9:16 AM
Revance Therapeutics (RVNC) Upgraded at ValuEngineRevance Therapeutics (RVNC) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:31 AM
Revance Therapeutics (RVNC) Buy Rating Reiterated at Cantor FitzgeraldRevance Therapeutics' (RVNC) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 9:10 PM
Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 InjectableRevance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
finance.yahoo.com - April 2 at 4:52 PM
Revance Therapeutics (RVNC) Cut to Hold at GuggenheimRevance Therapeutics (RVNC) Cut to Hold at Guggenheim
www.americanbankingnews.com - March 30 at 12:56 AM
Revance Therapeutics (RVNC) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowRevance Therapeutics (RVNC) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:46 PM
Revance Therapeutics Inc (RVNC) Receives Consensus Recommendation of "Buy" from BrokeragesRevance Therapeutics Inc (RVNC) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 27 at 1:38 AM

SEC Filings

Revance Therapeutics (NASDAQ:RVNC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Revance Therapeutics (NASDAQ:RVNC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Revance Therapeutics (NASDAQ RVNC) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.